IVERIC bio, Inc. Common Stock
ISEE
ISEE was delisted on the 10th of July, 2023.
0 hedge funds and large institutions have $0 invested in IVERIC bio, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 253 closing their positions.
100% less funds holding
Funds holding: 255 → 0 (-255)
100% less funds holding in top 10
Funds holding in top 10: 40 → 0 (-40)
100% less capital invested
Capital invested by funds: $5.33B → $0 (-$5.33B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 253
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$538M |
| 2 |
BlackRock
New York
|
-$424M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$317M |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$230M |
| 5 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
-$210M |
ISEE Hedge Fund Activity: Q3 2023 in Review
0 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in IVERIC bio, Inc. Common Stock (ISEE) for Q3 2023, worth a combined $0 — down 100% from $5.33B a quarter earlier.
Sellers outnumbered buyers: 253 funds closed out of ISEE and 0 opened new positions — a net loss of 253 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Vanguard Group, exiting entirely with an estimated $538M sold.
- 0 institutional investors held IVERIC bio, Inc. Common Stock (ISEE) as of Q3 2023, down from 255 in Q2 2023.
- Funds reported $0 of IVERIC bio, Inc. Common Stock stock for Q3 2023, down 100% quarter-over-quarter.
- 0 funds opened new IVERIC bio, Inc. Common Stock positions in Q3 2023 and 253 closed out, a net change of -253 holders.
- The largest IVERIC bio, Inc. Common Stock seller in Q3 2023 was Vanguard Group, an estimated $538M sold.
Based on aggregated 13F filings for Q3 2023.